Your browser doesn't support javascript.
loading
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
Powles, Thomas; Csoszi, Tibor; Özgüroglu, Mustafa; Matsubara, Nobuaki; Géczi, Lajos; Cheng, Susanna Y-S; Fradet, Yves; Oudard, Stephane; Vulsteke, Christof; Morales Barrera, Rafael; Fléchon, Aude; Gunduz, Seyda; Loriot, Yohann; Rodriguez-Vida, Alejo; Mamtani, Ronac; Yu, Evan Y; Nam, Kijoeng; Imai, Kentaro; Homet Moreno, Blanca; Alva, Ajjai.
Afiliação
  • Powles T; Barts Cancer Centre, St Bartholomew's Hospital, London, UK; Barts Cancer Institute, Barts Health NHS Trust, Queen Mary University of London, London, UK. Electronic address: thomas.powles1@nhs.net.
  • Csoszi T; County Oncology Centre, Hetényi Géza Hospital, Szolnok, Hungary.
  • Özgüroglu M; Cerrahpasa School of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey.
  • Matsubara N; National Cancer Center Hospital East, Chiba, Japan.
  • Géczi L; National Institute of Oncology, Budapest, Hungary.
  • Cheng SY; Sunnybrook Odette Cancer Centre, Toronto, ON, Canada.
  • Fradet Y; CHU de Québec-Université Laval, Quebec, QC, Canada.
  • Oudard S; Georges Pompidou European Hospital, University of Paris, Paris, France.
  • Vulsteke C; Center for Oncological Research (CORE), Antwerp University, Antwerp, Belgium; Integrated Cancer Center, Ghent, Belgium.
  • Morales Barrera R; Vall d'Hebron Institute of Oncology, Vall d' Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Fléchon A; Centre Léon Bérard, Lyon, France.
  • Gunduz S; Memorial Antalya Hospital, Antalya, Turkey; Minimally Invasive Therapeutics Laboratory, Mayo Clinic, AZ, USA.
  • Loriot Y; Institut Gustave Roussy, Université Paris-Saclay, Villejuif, Val-de-Marne, France.
  • Rodriguez-Vida A; Hospital del Mar, Barcelona, Spain.
  • Mamtani R; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
  • Yu EY; University of Washington, Seattle, WA, USA; Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Nam K; Merck, Kenilworth, NJ, USA.
  • Imai K; Merck, Kenilworth, NJ, USA.
  • Homet Moreno B; Merck, Kenilworth, NJ, USA.
  • Alva A; University of Michigan Health System, Ann Arbor, MI, USA.
Lancet Oncol ; 22(7): 931-945, 2021 07.
Article em En | MEDLINE | ID: mdl-34051178
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Bexiga Urinária / Carcinoma / Protocolos de Quimioterapia Combinada Antineoplásica / Urotélio / Anticorpos Monoclonais Humanizados / Antineoplásicos Imunológicos / Inibidores de Checkpoint Imunológico Tipo de estudo: Clinical_trials / Guideline / Prognostic_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Bexiga Urinária / Carcinoma / Protocolos de Quimioterapia Combinada Antineoplásica / Urotélio / Anticorpos Monoclonais Humanizados / Antineoplásicos Imunológicos / Inibidores de Checkpoint Imunológico Tipo de estudo: Clinical_trials / Guideline / Prognostic_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article